Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance oral etoposide vs observation after EP in extensive SCLC
ChiCTR-IIR-16008431Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in small cell lung cancer (SCLC) comparing Maintenance oral etoposide with Observation (2 arms). Primary endpoint: Progression-free survival. Planned start Jan 2016; status: not yet recruiting.
02
Drugs
etoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR-IIR-16008431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-16008431.